Back to trial details

Intake questionnaire

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Applying to Rush University Medical Center · Chicago, Illinois

Answer a few short questions to share with the research team.

0 of 4 answered

1. Are you 18 years old or older?
2. Have you been diagnosed with Non-Small Cell Lung Cancer?
3. Are you currently pregnant or breastfeeding?
4. Are you able to travel to Chicago for study visits?